LASIK-induced corneal changes after correction of hyperopia with and without application of Mitomycin-C
- PMID: 31014283
- PMCID: PMC6480872
- DOI: 10.1186/s12886-019-1100-7
LASIK-induced corneal changes after correction of hyperopia with and without application of Mitomycin-C
Abstract
Background: The study aimed to assess the role of intraoperative mitomycin-C (MMC) application during hyperopic LASIK correction (+ 1.00 D to + 6.00 D) by examining topographic corneal changes and incidence of regression over a one-year follow-up period.
Methods: This comparative randomized control study included 68 hyperopic patients (136 eyes) divided into two groups; Group A included 34 patients (68 eyes) that had LASIK with the application of 0.02% MMC for 10 s on the stromal bed after excimer laser treatment, and group B included 34 patients (68 eyes) that had LASIK without MMC application. Uncorrected distance visual acuity (UDVA), refraction, keratometry and topography were recorded at 1st week and 1st, 3rd, 6th, and 12th months postoperation. Predictability and treatment efficacy were also recorded at the end of the follow-up period.
Results: Better predictability was noted in group A than in group B at the 6 month and 12 month follow-up visits, with a mean cycloplegic refraction SE of + 0.5 ± 0.31 D in group A and + 0.67 ± 0.39 D in group B at the 6 month visit, and + 0.63 ± 0.37 D in group A and + 0.89 ± 0.48 D in group B at the 12 month visit. The efficacy of the treatment at the end of the follow up period was better in group A than in group B. Group A showed fewer topographic corneal changes than group B.
Conclusions: Intraoperative MMC application during hyperopic LASIK achieves better predictability and efficacy and induces fewer topographic changes and lower regression rate of hyperopia during the first postoperative year.
Trial registration: the Pan African Clinical Trial Registry PACTR201901543722087 , on 29 January 2019.
Keywords: Hyperopic LASIK - regression; Mitomycin-C.
Conflict of interest statement
Ethics approval and consent to participate
Informed written consent was obtained from all study individuals. This study was approved by the Departmental Research Committee and Research Ethics Committee, Faculty of medicine, Suez Canal University on (14/2/2016) with a reference number (research #2717) and followed the tenets of Declaration of Helsinki.
Consent for publication
Consent for the publication of identifying images or other personal or clinical details of participants that compromise anonymity is not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Figures







Similar articles
-
Femtosecond Laser-Assisted LASIK With and Without the Adjuvant Use of Mitomycin C to Correct Hyperopia.J Refract Surg. 2018 Jan 1;34(1):23-28. doi: 10.3928/1081597X-20171116-01. J Refract Surg. 2018. PMID: 29315438
-
Hyperopic laser in situ keratomileusis: primary and secondary treatments are safe and effective.Cornea. 2001 May;20(4):388-93. doi: 10.1097/00003226-200105000-00010. Cornea. 2001. PMID: 11333326
-
Changes of Functional Optical Zone After LASIK for Hyperopia and Hyperopic Astigmatism.J Refract Surg. 2018 Jul 1;34(7):476-481. doi: 10.3928/1081597X-20180515-03. J Refract Surg. 2018. PMID: 30001451
-
Laser in situ keratomileusis for consecutive hyperopia after myopic LASIK and radial keratotomy.J Cataract Refract Surg. 2003 May;29(5):879-88. doi: 10.1016/s0886-3350(03)00051-8. J Cataract Refract Surg. 2003. PMID: 12781270
-
Laser in situ keratomileusis for the correction of hyperopia from +1.25 to +5.00 diopters with the Technolas Keracor 117C laser.J Refract Surg. 2001 Mar-Apr;17(2):113-22. doi: 10.3928/1081-597X-20010301-04. J Refract Surg. 2001. PMID: 11310760
Cited by
-
Twelve-month outcomes of single-step transepithelial photorefractive keratectomy for moderate hyperopia and hyperopic astigmatism.Eye Vis (Lond). 2023 Mar 1;10(1):7. doi: 10.1186/s40662-023-00327-4. Eye Vis (Lond). 2023. PMID: 36855211 Free PMC article.
-
Transient Mitomycin C-treatment of human corneal epithelial cells and fibroblasts alters cell migration, cytokine secretion, and matrix accumulation.Sci Rep. 2019 Sep 25;9(1):13905. doi: 10.1038/s41598-019-50307-9. Sci Rep. 2019. PMID: 31554858 Free PMC article.
-
Effect of Transepithelial Photorefractive Keratectomy without Mitomycin C in the Treatment of Femtosecond Laser In Situ Keratomileusis Corneal Flap Complications.J Ophthalmol. 2021 Jan 13;2021:8847922. doi: 10.1155/2021/8847922. eCollection 2021. J Ophthalmol. 2021. PMID: 33520302 Free PMC article.
-
Transepithelial Photorefractive Keratectomy for Hyperopia Correction: An Uncharted Territory.Clin Ophthalmol. 2023 May 30;17:1497-1504. doi: 10.2147/OPTH.S415636. eCollection 2023. Clin Ophthalmol. 2023. PMID: 37273504 Free PMC article. Review.
-
Early Outcomes of Two Treatment Modes of PresbyLASIK: Monocular vs. Micro-Monovision.Clin Ophthalmol. 2022 Nov 1;16:3597-3606. doi: 10.2147/OPTH.S384553. eCollection 2022. Clin Ophthalmol. 2022. PMID: 36345532 Free PMC article.
References
-
- Anschutz T. Laser correction of hyperopia and presbyopia. Int Ophthalmol Clin. 1994;42:139–143. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources